Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Spondyloarthropathies Spondyloarthropathies for November/December 2020 Etanercept may not help some with suspected nonradiographic axial spondyloarthritis, More must reads Spondyloarthropathies for September/October 2020 Novel study explores link between primary immunodeficiencies, rheumatic diseases, Lower TNF inhibitor efficacy observed in women with nonradiographic axSpA, Shingrix effective in older adults with preexisting immune-mediated disorders, Trabecular bone loss may contribute to axial spondyloarthritis progression, More must readsSpondyloarthropathies for July/August 2020 Obesity negatively affects axial spondyloarthritis disease activity, Trio of antibodies may enable earlier diagnosis of axSpA, More must readsSpondyloarthropathies for May/June 2020 New registry focuses on rheumatic immune-related AEs of cancer therapy, Studies give new insight on starting, stopping etanercept in nonradiographic axSpA, TICOSPA: Efficacy of treat-to-target strategy suggested in axial spondyloarthritis, Age leads COVID-19 hospitalization risk factors in RMDs, Some biologics may be better than others for averting anterior uveitis, More must readsSpondyloarthropathies for March/April 2020 Sacroiliac bone marrow edema on MRI may be common postpartum, Financial incentives affect the adoption of biosimilars, Treatment for RA, SpA may not affect COVID-19 severity, Rapid shift to adalimumab biosimilars in Denmark contrasts with U.S. experience, Reduced TNFi dose does not maintain axial spondyloarthritis improvement, More must readsPages1 2 3 4 last ยป
